Drug Profile


Alternative Names: A110; BSYX-A110; HU 96110

Latest Information Update: 26 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Applied Molecular Evolution; Biosynexus
  • Developer Biosynexus
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Lipoteichoic acid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Staphylococcal infections
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Staphylococcal infections

Most Recent Events

  • 07 Dec 2010 Biosynexus completes enrolment in its phase II/III trial for Staphylococcal infections in USA (MAB-N007)
  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 13 Jun 2006 This monoclonal antibody is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top